Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nab-paclitaxel or paclitaxel + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This entry refers to two related multi-drug regimens used primarily in oncology. The first regimen, carboplatin plus nab-paclitaxel, is commonly known as "nab-PC" and is indicated for advanced non-small cell lung cancer (NSCLC) and gynecological cancers such as ovarian, endometrial, and cervical cancer[2][8]. Nab-paclitaxel (Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel that disrupts microtubule function, inhibiting cell division[5][8]. Carboplatin is a platinum-based alkylating agent that causes DNA crosslinking and apoptosis in rapidly dividing cells[7][8]. The second regimen combines either standard paclitaxel or nab-paclitaxel with carboplatin and the immune checkpoint inhibitor pembrolizumab (Keytruda), which blocks PD-1 on T cells to enhance anti-tumor immunity. This combination has been approved for use in several cancers including NSCLC and triple-negative breast cancer[6][7]. These regimens are administered intravenously in cycles.
- Other names
- nab-PCCarboTaxolPC
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + nab-paclitaxel or paclitaxel + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nab-paclitaxel or paclitaxel + pembrolizumab.